Narcolepsy Clinical Trial
Official title:
The Role of the Orexin System in Body Weight Regulation: Patients With Narcolepsy
This study will measure energy expenditure (the rate at which the body burns calories),
physical activity and caloric intake in people with narcolepsy to learn more about how the
risk of becoming overweight or diabetic may be affected.
Healthy control subjects and people with narcolepsy between 18 and 55 years of age may be
eligible for this study. Participants are withdrawn from their narcolepsy medication and
undergo the following tests and procedures over 5 weeks before resuming medications.
- Blood draw for genetic studies.
- Collection of a cerebrospinal fluid sample.
- Diet to keep subjects' weight constant.
- Activity watch, using a device worn on the wrist to measure amount of movement, and an
activity monitor worn at the waist to measure physical activity and caloric expenditure.
- Questionnaires about sleepiness, symptoms, food intake, exercise and mood.
- 24-hour urine collection and 24-hour blood draw to measure hormones.
- Glucose tolerance test. The subject drinks a sugar solution and blood samples are
collected through a catheter before drinking the solution and 30 minutes, 1, 2 and 3
hours after drinking it.
- Startle reflex test. Subjects hear a loud noise through headphones and are asked to look
at pictures.
- Sleep study to evaluate sleep-related breathing disturbances and record information
about sleep stages.
- Indirect calorimetry test to measure how fast the body uses calories. A plastic canopy
is placed over the face for several minutes to capture the air exhaled to analyze oxygen
use. To measure the energy associated with meals, the same measurements are taken after
the subject eats lunch.
- CT scan of the abdomen to see how much fat is deposited in the abdomen, and DEXA scan of
the whole body to see the percentage of fat and muscle.
- Plethysmography. Participants sit in an enclosed chamber while the mass and volume of
the body are measured by changes in air pressure.
- Neuropsychological testing to assess thought processes.
- Continuous 24-hour heart rate measurement.
- Metabolic chamber. Subjects spend 24 hours in a small room to measure the amount of
oxygen inhaled and carbon dioxide exhaled.
- Walking/running test to assess level of physical conditioning.
- Dexamethasone CRH (corticotropin-releasing hormone) suppression test and CRH stimulation
test. Subjects receive eight doses of 0.5 mg dexamethasone every 6 hours for a day and a
half. After the last dose, two blood samples are drawn, then a dose of CRH is injected,
and then six more blood samples are drawn over the next 3 hours.
- TRH (thyrotropin-releasing hormone) stimulation test. Subjects are given TRH through a
vein, and several blood samples are then drawn over the next 3 hours.
- Doubly labeled water test. Subjects drink a dose of "heavy" water. Urine samples are
collected at 2, 3 and 5 hours after drinking and again for two 4-hour collections a week
later.
BACKGROUND: Several cross-sectional studies have suggested that subjects with narcolepsy have
increased body mass index (BMI) and insulin resistance. These subjects exhibit a decrease in
cerebrospinal fluid (CSF) orexin levels, which has been causally linked to the clinical
manifestations of this disease. Orexins are peptides expressed in a brain region, the lateral
hypothalamic area, which stimulate appetite and modulate sleep. Low CSF orexin levels provoke
narcolepsy-like behavior, such as excessive daytime sleepiness and a sudden loss of muscle
tone known as cataplexy.
OBJECTIVES: The primary objective of this study is to determine whether subjects with
narcolepsy have lower energy expenditure compared to healthy matched controls. In addition,
we will assess food intake, physical activity, and other relevant parameters.
STUDY POPULATION: 18 to 55 year old men and premenopausal women with narcolepsy and healthy
matched controls
DESIGN: This is a cross-sectional, case-controlled study of subjects with narcolepsy matched
on a one-to-one basis with healthy, non-narcoleptic control subjects.
OUTCOME PARAMETERS: We will assess metabolic, hormonal, and energy expenditure parameters in
subjects with narcolepsy. Outcomes: energy expenditure by various methods (indirect
calorimetry, metabolic chamber, doubly-labeled water method); leptin circadian levels
(frequent 24h sampling); physical activity, characterization of the main endocrine axes, and
other relevant parameters.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04072380 -
A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy
|
Phase 2 | |
Withdrawn |
NCT03626727 -
Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia
|
Early Phase 1 | |
Completed |
NCT02821715 -
Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients
|
Phase 2 | |
Completed |
NCT01681121 -
A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy
|
Phase 2 | |
Completed |
NCT01789398 -
Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV)
|
Phase 3 | |
Completed |
NCT00174174 -
Provigil (Modafinil) Study by Taiwan Biotech Co.
|
N/A | |
Completed |
NCT05059223 -
A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy
|
Phase 3 | |
Completed |
NCT04923594 -
Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy
|
Phase 2 | |
Recruiting |
NCT06279247 -
Proteomics and Metabolomics of Body Fluid in Patients With Narcolepsy
|
||
Completed |
NCT04647903 -
Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR)
|
Phase 1 | |
Completed |
NCT03267303 -
A Study to Evaluate the Safety and Efficacy of TS-091 in Patients With Narcolepsy
|
Phase 2 | |
Completed |
NCT03173378 -
Evaluation of Academic and Professional Trajectories of Narcoleptic Patients
|
||
Completed |
NCT05055024 -
An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy
|
Phase 2 | |
Completed |
NCT01067235 -
Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy
|
Phase 3 | |
Completed |
NCT00228566 -
Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome
|
Phase 3 | |
Completed |
NCT00107796 -
Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy
|
Phase 3 | |
Completed |
NCT00107848 -
PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome
|
Phase 3 | |
Completed |
NCT00132873 -
Trial of Xyrem® (Sodium Oxybate) for the Treatment of Narcolepsy
|
Phase 3 | |
Enrolling by invitation |
NCT05113745 -
A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy
|
Phase 3 | |
Suspended |
NCT04419792 -
'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy'
|